研究者詳細 - 齋藤　竜太

論文 - 齋藤　竜太

分割表示 361 件中 181 - 200 件目／全件表示 >>

Dissecting the molecular complexity underlying glioblastoma by genomic and transcriptome profiling

Nakashima, T, Funakoshi, Y, Nambu, S, Uneda, A, Katayama, K, Hanaya, R, Imoto, S, Tanaka, S, Saito, R, Yoshimoto, K, Narita, Y, Yoshimoto, K, Narita, Y, Suzuki, H

CANCER SCIENCE 114 巻頁： 205 - 205 2023年2月

Identification of therapeutic targets exhibiting synthetic lethality with IDH1 inhibitor using the CRISPR/Cas9 system

Maeda, S; Aoki, K; Hinohara, K; Yamaguchi, J; Ohka, F; Natsume, A; Saito, R

CANCER SCIENCE 114 巻頁： 1460 - 1460 2023年2月

Intra-operative analysis of genetic alterations in brain tumor using rapid quantitative PCR device

Ohka, F; Maeda, S; Yamaguchi, J; Motomura, K; Saito, R

CANCER SCIENCE 114 巻頁： 1818 - 1818 2023年2月

Whole genome multi-omics landscape of Oligodenderoglioma, IDH-mutant and 1p/19q-codeleted

Funakoshi, Y; Nambu, S; Nakashima, T; Uneda, A; Katayama, K; Imoto, S; Hanaya, R; Tanaka, S; Saito, R; Yoshimoto, K; Narita, Y; Suzuki, H

CANCER SCIENCE 114 巻頁： 206 - 206 2023年2月

Whole-genome sequencing and comprehensive molecular profiling of Astrocytoma, IDH-mutant

Funakoshi, Y; Nakashima, T; Nambu, S; Uneda, A; Katayama, K; Imoto, S; Hanaya, R; Tanaka, S; Saito, R; Yoshimoto, K; Narita, Y; Suzuki, H

CANCER SCIENCE 114 巻頁： 203 - 203 2023年2月

A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas. 査読有り国際誌

Yoshihiro Muragaki, Eiichi Ishikawa, Takashi Maruyama, Masayuki Nitta, Taiichi Saito, Soko Ikuta, Takashi Komori, Takakazu Kawamata, Tetsuya Yamamoto, Koji Tsuboi, Akira Matsumura, Hideo Nakamura, Junichiro Kuroda, Tatsuya Abe, Yasutomo Momii, Ryuta Saito, Teiji Tominaga, Yusuke Tabei, Ichiro Suzuki, Yoshiki Arakawa, Susumu Miyamoto, Masao Matsutani, Katsuyuki Karasawa, Yoichi Nakazato, Katsuya Maebayashi, Koichi Hashimoto, Tadao Ohno

Journal of neurosurgery 頁： 1 - 11 2023年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: An autologous formalin-fixed tumor vaccine (AFTV) derived from resected glioblastoma (GBM) tissue can be used against unidentified tumor antigens. Thus, the authors conducted a multicenter double-blind phase IIb trial to investigate the efficacy of an AFTV. METHODS: Eligible patients were adults with supratentorial GBMs, 16-75 years of age, with Karnofsky Performance Scale (KPS) scores ≥ 60%, and no long-term steroid administration. An AFTV comprising fixed paraffin-embedded tumor tissue with immune adjuvants or an identical placebo without fixed tumor tissue was injected intradermally over three courses before and after chemoradiotherapy. The primary and secondary end points were overall survival (OS), progression-free survival (PFS), and 3-year survival rate. RESULTS: Sixty-three patients were enrolled. The average patient age was 61 years. The median KPS score was 80%, and the median resection rate was 95%. The full analysis set of 57 patients indicated no significant difference in OS (p = 0.64) for the AFTV group (median OS 25.6 months, 3-year OS rate 38%) compared with the placebo group (31.5 months and 41%, respectively) and no difference in PFS (median PFS 13.3 months in both groups, p = 0.98). For patients with imaging-based total tumor removal, the 3-year PFS rate was 81% in the AFTV group versus 46% in the placebo group (p = 0.067), whereas the 3-year OS rate was 80% versus 54% (p = 0.16), respectively. Similar results were obtained in the p53-negative subgroups. Severe adverse effects were not observed. CONCLUSIONS: The AFTV may have potential effects in certain patient subgroups. A phase III study for patients with total tumor removal remains warranted to confirm these findings. Clinical trial registration no.: UMIN000010602 (UMIN Clinical Trials Registry).

DOI： 10.3171/2022.12.JNS221221

PubMed

researchmap

Imaging features of localized <i>IDH</i> wild-type histologically diffuse astrocytomas: a single-institution case series 査読有り国際誌 Open Access

Kibe, Y; Motomura, K; Ohka, F; Aoki, K; Shimizu, H; Yamaguchi, J; Nishikawa, T; Saito, R

SCIENTIFIC REPORTS 13 巻 ( 1 ) 頁： 23 - 23 2023年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Scientific Reports

Isocitrate dehydrogenase wild-type (IDHwt) diffuse astrocytomas feature highly infiltrative patterns, such as a gliomatosis cerebri growth pattern with widespread involvement. Among these tumors, localized IDHwt histologically diffuse astrocytomas are rarer than the infiltrative type. The aim of this study was to assess and describe the clinical, radiographic, histopathological, and molecular characteristics of this rare type of IDHwt histologically diffuse astrocytomas and thereby provide more information on how its features affect clinical prognoses and outcomes. We retrospectively analyzed the records of five patients with localized IDHwt histologically diffuse astrocytomas between July 2017 and January 2020. All patients were female, and their mean age at the time of the initial treatment was 55.0 years. All patients had focal disease that did not include gliomatosis cerebri or multifocal disease. All patients received a histopathological diagnosis of diffuse astrocytomas at the time of the initial treatment. For recurrent tumors, second surgeries were performed at a mean of 12.4 months after the initial surgery. A histopathological diagnosis of glioblastoma was made in four patients and one of gliosarcoma in one patient. The initial status of IDH1, IDH2, H3F3A, HIST1H3B, and BRAF was “wild-type” in all patients. TERT promoter mutations (C250T or C228T) were detected in four patients. No tumors harbored a 1p/19q codeletion, EGFR amplification, or chromosome 7 gain/10 loss (+ 7/ − 10). We assessed clinical cases of localized IDHwt histologically diffuse astrocytomas that resulted in malignant recurrence and a poor clinical prognosis similar to that of glioblastomas. Our case series suggests that even in patients with histologically diffuse astrocytomas and those who present with radiographic imaging findings suggestive of a localized tumor mass, physicians should consider the possibility of IDHwt histologically diffuse astrocytomas.

DOI： 10.1038/s41598-022-25928-2

Concurrent cerebral infarction and intracranial tuberculoma induced by the carotid plaque complicated with miliary tuberculosis 査読有り国際誌

Muraoka, S; Oguri, T; Kimura, R; Sakurai, K; Suzuki, Y; Shimizu, H; Shinoda, S; Koketsu, N; Araki, Y; Saito, R

ACTA NEUROCHIRURGICA 165 巻 ( 3 ) 頁： 647 - 650 2023年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Neurochirurgica

Cerebrovascular complications of central nervous system tuberculosis (TB) are predictors of poor prognosis and adverse outcomes. These complications are mainly intracranial arterial involvement, with occasional venous involvement. Here, we present a 67-year-old woman with concurrent cerebral infarction and intracranial tuberculoma induced by the carotid plaque complicated by miliary tuberculosis. Mycobacterium tuberculosis was observed on the luminal side of the carotid plaques in pathological specimens. Treatment with anti-TB drugs alone would likely not cure the patient, as M. tuberculosis would continue to disseminate. Endarterectomy could directly remove the embolic source, and a complete cure was achieved.

DOI： 10.1007/s00701-023-05489-7

Cutoff values for the best management strategy for magnetic resonance-guided focused ultrasound ablation for essential tremor 査読有り国際誌

Torii, J; Maesawa, S; Nakatsubo, D; Tsugawa, T; Kato, S; Ishizaki, T; Takai, S; Shibata, M; Wakabayashi, T; Tsuboi, T; Suzuki, M; Saito, R

JOURNAL OF NEUROSURGERY 138 巻 ( 1 ) 頁： 38 - 49 2023年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of Neurosurgery

OBJECTIVE The efficacy of magnetic resonance–guided focused ultrasound (MRgFUS) ablation for essential tremor (ET) is well known; however, no prognostic factors have been established. The authors aimed to retrospectively investigate MRgFUS ablation outcomes and associated factors and to define the cutoff values for each prognostic factor. METHODS Sixty-four Japanese patients who underwent unilateral ventral intermediate nucleus thalamotomy with MRgFUS for ET were included. Follow-up evaluations were performed at 1 week and 1, 3, 6, 12, and 24 months postoperatively. Tremor suppression was evaluated using the Clinical Rating Scale for Tremor (CRST), and adverse effects were recorded postoperatively. Outcome-associated factors were examined preoperatively, intraoperatively, and postoperatively using multivariate analyses. The cutoff values for the prognostic factors were calculated using receiver operating characteristics. RESULTS Percentage improvements in the CRST scores of the affected upper limb were 82.4%, 72.2%, 68.6%, and 65.9% at 1, 3, 6, and 12 months, respectively. Preoperatively, a high skull density ratio (SDR) (p ≤ 0.047), low CRST part B score (used to assess tremors during several tasks) (cutoff value 25, p ≤ 0.041), and nonoccurrence of resting tremors (p = 0.027) were significantly associated with improved tremor control. An intraoperatively high maximum mean temperature (cutoff value 52.5°C, p ≤ 0.047), postoperatively large lesion (cutoff value 3.9 mm in the anterior-posterior direction, p ≤ 0.002; cutoff value 5.0–5.55 mm in the superior-inferior direction, p ≤ 0.026), and small transducer focus correction (p ≤ 0.015) were also associated with improved tremor control. No valid cutoff value was found for SDR. Adverse effects (limb weakness, sensory disturbance, ataxia/walking disturbance, dysgeusia, dysarthria, and facial swelling) occurred transiently and were associated with high SDR, high temperature, high number of sonication sessions, large lesion, and occurrence of resting tremor. Patients who developed leg weakness experienced greater percentage improvement in tremors at 3 months postoperatively than those who did not. CONCLUSIONS MRgFUS ablation could be used to achieve good tremor control with acceptable adverse effects in Japanese patients with ET. The relatively low SDR in Asian ethnic groups as compared with that of Western populations makes treatment difficult; however, the cutoff values obtained in this study may be useful for achieving good treatment outcomes even in such patients.

DOI： 10.3171/2022.3.JNS212460

[Seizure Semiology and Functional Anatomy in the Cerebral Cortex].

Maesawa S, Ishizaki T, Saito R

No shinkei geka. Neurological surgery 51 巻 ( 1 ) 頁： 17 - 28 2023年1月

振戦優位型パーキンソン病(TD-PD)におけるMRガイド下集束超音波治療(MRgFUS)の適応判断と治療効果の検討

中坪大輔, 前澤聡, 津川隆彦, 加藤祥子, 鳥居潤, 武藤学, 伊藤芳記, 坪井崇, 鈴木将史, 若林俊彦, 勝野雅央, 齊藤竜太

日本定位・機能神経外科学会プログラム・抄録集 62回巻頁： 133 - 133 2023年1月

再発小児悪性脳腫瘍に対する手術療法

園田順彦, 松田憲一朗, 伊藤美以子, 齋藤竜太, 金森政之, 金村米博, 冨永悌二

小児の脳神経 48 巻 ( 1 ) 頁： 33 - 38 2023年

記述言語：日本語出版者・発行元：一般社団法人日本小児神経外科学会

<p>7例の小児悪性脳腫瘍を対象に再手術の有用性に関して検討を行った．上衣腫4例の再発までの期間は10～35か月であり，3例は長期生存を得ているが1例は髄腔内播種を来し死亡した．膠芽腫の2例は再発までの期間が短く，全生存期間は1年前後と不良であった．分子生物学的にはIDH1変異，H3 G34変異が認められた．1歳の髄芽腫は分子生物学的にはSHH TP53野生型であり，再摘出と化学療法のみで経過観察とし長期間にわたり寛解を得ている．全例，手術合併症は軽度で，生存例はKPS80以上を維持できている．</p>

DOI： 10.34544/jspn.48.1_33

CiNii Research

researchmap

Investigation of cystine as differential diagnostic biomarker between astrocytomas and oligodendrogliomas based on global- and targeted analysis using liquid chromatography/tandem mass spectrometric analysis 査読有り

Masahiro Watanabe, Masamitsu Maekawa, Masayuki Kanamori, Minami Yamauchi, Ai Abe, Yoshiteru Shimoda, Ryuta Saito, Hidenori Endo, Nariyasu Mano

Advances in Biomarker Sciences and Technology 5 巻頁： 76 - 85 2023年

Usefulness of Stanch Belt Plus in Postoperative Management after Endovascular Neurosurgery 査読有り国際誌

Nishihori, M; Kawase, R; Izumi, T; Nakase, H; Onishi, E; Saito, R

JOURNAL OF NEUROENDOVASCULAR THERAPY 17 巻 ( 12 ) 頁： 281 - 285 2023年

Latest Treatments and Expectations for Precision Medicine against Malignant Glioma 招待有り査読有り Open Access

Saito R

Japanese Journal of Neurosurgery 32 巻 ( 3 ) 頁： 148 - 153 2023年

担当区分：筆頭著者,　最終著者,　責任著者記述言語：日本語出版者・発行元：Japanese Journal of Neurosurgery

Malignant glioma is one of the most intractable malignant neoplasms. Standard treatment consists of surgery, radiotherapy, and chemotherapy, although substantial therapeutic effects cannot be expected. In particular, the blood‒brain barrier（BBB）protects the central nervous system, reducing the effectiveness of chemotherapy. Temozolomide is the standard treatment, but it only prolongs the median survival time by about two months compared to surgery and radiation. Molecular‒targeted therapies, which have revo-lutionized the treatment of many cancer types, have all failed to treat malignant gliomas, and the focus is now on the spatial and temporal diversity of tumors. In addition, the problem of drug penetration across the BBB has been refocused. Precision medicine is also attracting great expectations, but panel testing can only be done once. Even if an expert panel recommends a treatment, there is a problem in that most treatments have to rely on investigational therapies. It is also known that even if there is a draggable genetic abnormality in tumors, drugs targeting those abnormalities are often ineffective against brain tumors. Therefore, it is necessary that all novel therapeutic approaches, such as virus therapy, neutron capture therapy, and drug delivery techniques like convection‒enhanced delivery, be employed to improve treatment outcomes in malignant glioma. （Received September 12, 2022；accepted January 25, 2023）.

DOI： 10.7887/jcns.32.148

Unique vascular structures of a radicular arteriovenous fistula at the craniocervical junction along the first cervical spinal nerve: A case report. 国際誌 Open Access

Wada K, Tanei T, Hattori K, Hatano H, Fujitani S, Ito R, Kubo H, Nishimura Y, Maesawa S, Saito R

Surgical neurology international 14 巻頁： 85 - 85 2023年

記述言語：英語出版者・発行元：Surgical Neurology International

Background: An arteriovenous fistula (AVF) at the craniocervical junction (CCJ) is a rare vascular malformation. Definitive diagnosis and curative treatment of CCJ AVF are challenging. Case Description: A 77-year-old man presented with subarachnoid hemorrhage. Cerebral angiography showed an AVF at the CCJ, which drained into a radicular vein. The lesion was fed by a vertebral artery, anterior and lateral spinal arteries (LSAs), and the occipital artery (OA). There were two unique structures: the LSA originating from the posterior inferior cerebellar artery of the extracranial V3 segment and the OA feeding the shunt. Curative treatment involved two steps: endovascular embolization of feeders using Onyx and surgical shunt disconnection. Feeding arteries were blackened by Onyx, which helped identify the location of the shunt. The shunt was located behind the first cervical (C1) spinal nerve, and the draining vein was confirmed on the deep side of the nerve. A clip was applied to the draining vein distal to the shunt. Tiny vessels supplying the shunt were then coagulated referring to blackened arteries. Conclusion: A radicular AVF at the CCJ along the C1 spinal nerve had unique vascular structures. Definitive diagnosis and curative treatment were achieved by combining endovascular embolization using Onyx and direct surgery.

DOI： 10.25259/SNI_122_2023

Speech-language Pathology Rehabilitation in a Case of Jefferson Fracture Complicated with Lower Cranial Nerve Palsies.

Horiike S, Nakajima Y, Matsuo M, Kageyama A, Motomura A, Tsujiuchi T, Saito R

NMC case report journal 10 巻 ( 0 ) 頁： 157 - 162 2023年

Simultaneous Aneurysmal Subarachnoid Hemorrhage and Epistaxis in an Untreated Prolactinoma: A Case Report and Literature Review.

Nishihori M, Izumi T, Takeuchi K, Goto S, Kanamori F, Uda K, Yokoyama K, Araki Y, Saito R

NMC case report journal 10 巻 ( 0 ) 頁： 163 - 168 2023年

Sacral arteriovenous fistula with lower thoracic cord edema without perimedullary vein enlargement. Open Access

Ishii M, Nishimura Y, Nagashima Y, Tanei T, Nishihori M, Izumi T, Saito R

Surgical neurology international 14 巻頁： 295 2023年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Surgical Neurology International

Background: Sacral dural arteriovenous fistulas (AVFs) are often undiagnosed at the initial presentation due to their rarity. Case Description: For 1 year, a 71-year-old man developed progressive motor and sensory disturbances in both legs. Magnetic resonance imaging showed spinal cord edema with mild contrast enhancement at the T9–10 and T12 levels. Although mild venous dilatation was observed only at the cauda equina level, it was not initially recognized as abnormal. Blood and cerebrospinal fluid tests and spinal angiography of the lower thoracic to upper lumbar levels were nonspecific. The patient was unsuccessfully treated with three courses of high-dose intravenous methylprednisolone. Ultimately, following repeat spinal angiography (i.e., including the bilateral internal iliac arteries) that revealed a low-flow sacral dural AVF supplied by the right lateral sacral artery, the patient underwent successful surgical venous AVF occlusion/transection. Conclusion: In cases of spinal cord edema without perimedullary abnormal flow voids, careful spinal angiography including the sacral spine is necessary even if only minimal venous dilation is initially observed at the cauda equina level.

DOI： 10.25259/SNI_606_2023

Ruptured Middle Cerebral Artery Aneurysm in an Infant: Case Report and Literature Review.

Yokoyama H, Nishihori M, Izumi T, Goto S, Kurimoto M, Kato M, Kanamori F, Uda K, Yokoyama K, Araki Y, Saito R

NMC case report journal 10 巻 ( 0 ) 頁： 177 - 183 2023年

　前のページ - 次のページ　

<齋藤 竜太>

論文 - 齋藤 竜太

<齋藤　竜太>

論文 - 齋藤　竜太